John K Chan, MD
Gynecological Oncology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 31 years
- University of California, Geffen School of Medicine, 1995
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: California Pacific Medical Center - Mission Bernal · California Pacific Medical Center- Van Ness Campus · California Pacific Medical Ctr-Davies Campus Hosp · Mills-Peninsula Medical Center · Novato Community Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Chan’s office at (415) 751-1847 to ask if they take your plan before you enroll.
California Medical Board record
Licence A61661 · Current
Licensed to practise in California · since 1997 · expires 2029-02-28 · University of California, Los Angeles School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Obstetrics and Gynecology - Gynecologic Oncology
- American Board of Obstetrics and Gynecology - Obstetrics and Gynecology
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center - Mission BernalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.322, Oct 2024 – Sep 2025
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- California Pacific Medical Ctr-Davies Campus HospSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.187, Oct 2024 – Sep 2025
- Novato Community HospitalNovato, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center - Mission Bernal
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 3 the same, 3 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.322 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.19 to 2.28) · 336 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.47 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 163.19 (101.27 to 225.11) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.4 · 177 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 32 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,281 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 2,912 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 2,681 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.07 (1.81 to 6.33) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 425 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.46 (0.79 to 4.12) · 755 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.36 (0 to 16.38) · 431 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.47 (1.38 to 9.55) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.2 to 3.2) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 1.16) · 2,291 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.4 · 369 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.602 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.618 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 242 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 20.9 · 197 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.6 · 203 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 292 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 74 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 110 cases | No different | Jan 2024 – Dec 2024 |
What patients said (406 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for California Pacific Medical Ctr-Davies Campus Hosp
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 1 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.187 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 232 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.56 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 10 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 257 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 721 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 2,031 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.45) · 2,032 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.35 (0.94 to 5.76) · 419 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 211 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.84 (1.24 to 4.44) · 414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.95 (2.91 to 20.98) · 218 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.61 (1.47 to 9.75) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 52 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.28) · 1,461 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 58 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.756 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 91 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 65.3 · 84 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -26.6 · 115 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 55 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 25 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 312 cases | No different | Jan 2024 – Dec 2024 |
What patients said (602 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Novato Community Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.06) · 213 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.4 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 25 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10 · 111 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.1 · 140 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.3 · 42 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 627 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,872 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 1,796 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.92 (0.5 to 5.33) · 505 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.36) · 317 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.2 (0.51 to 3.88) · 495 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.93 (0 to 17.29) · 323 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.88 (0.69 to 9.07) · 311 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.22 to 3.27) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.41 (0 to 1.49) · 1,320 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 143 cases | None | Apr 2023 – Mar 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 108 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.9 · 121 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.1 · 150 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 118 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 27 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.5 to 16.5) · 930 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 184 cases | No different | Jan 2024 – Dec 2024 |
What patients said (334 patients answered, 30% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 84% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$140,805
Medicare paid this office $140,805 for 202 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 78 | $18,607 | $112 |
| Long return visit (40+ min) | 51 | $18,084 | $161 |
| Short return visit (20+ min) | 117 | $13,155 | $78 |
| New patient visit (60+ min) | 57 | $11,264 | $198 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 11 | $9,049 | $823 |
Procedures Medicare counted
| Colonoscopy | 1-10 | None |
| Hernia repair (minimally invasive) | 1-10 | None |
| Removal of the uterus | 39 | More than 98% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 17 | 27 | 24 | – | 14 | 11 |
| Removal of lymph nodes of both sides of pelvis and abdominal lymph node biopsy using an endoscope | 16 | 11 | 12 | – | 11 | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
202 Original Medicare patients in 2024. Average age 73 · Women 100% · Also on Medicaid 12% · Health risk score 1.26. At or below the middle of the specialty; the typical gynecological oncology clinician is at 1.53.
Conditions among them: High blood pressure 57% · Cancer 41% · Diabetes 20% · Depression 19% · Chronic kidney disease 15% · Coronary heart disease 13% · Heart failure 8% · COPD 8% · Atrial fibrillation 8%.
The office billed $593,705, Medicare allowed $182,135 and paid $140,805; for 606 services of 37 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 202 | 606 | 73 | 1.26 | $593,705 | $140,805 |
| 2023 | 192 | 518 | 74 | 1.47 | $541,678 | $131,396 |
| 2022 | 214 | 575 | 74 | 1.53 | $538,216 | $132,001 |
| 2021 | 208 | 644 | 73 | 1.38 | $621,634 | $155,714 |
| 2020 | 242 | 713 | 73 | 1.45 | $638,472 | $154,997 |
| 2019 | 253 | 698 | 72 | 1.33 | $715,397 | $171,383 |
| 2018 | 268 | 794 | 72 | 1.37 | $829,332 | $188,974 |
| 2017 | 242 | 709 | 72 | 1.28 | $718,205 | $160,276 |
| 2016 | 214 | 551 | 72 | 1.22 | $574,280 | $135,391 |
| 2015 | 194 | 513 | 73 | 1.21 | $639,076 | $162,141 |
| 2014 | 152 | 353 | 72 | 1.03 | $453,784 | $106,419 |
| 2013 | 175 | 479 | 71 | 1.40 | $381,762 | $75,385 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Long return visit (40+ min) | 55 | $21,318 | $163 |
| Return visit (30+ min) | 84 | $13,042 | $115 |
| New patient visit (60+ min) | 65 | $12,220 | $188 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 14 | $11,093 | $792 |
| Short return visit (20+ min) | 77 | $7,843 | $78 |
| Removal of lymph nodes of both sides of pelvis and abdominal lymph node biopsy using an endoscope | 11 | $4,925 | $448 |
2022: 4 services
| Long return visit (40+ min) | 70 | $25,143 | $157 |
| Return visit (30+ min) | 80 | $13,779 | $110 |
| New patient visit (60+ min) | 68 | $13,307 | $196 |
| Short return visit (20+ min) | 81 | $7,875 | $72 |
2021: 6 services
| Long return visit (40+ min) | 70 | $25,386 | $166 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 24 | $18,448 | $769 |
| Return visit (30+ min) | 78 | $15,819 | $115 |
| New patient visit (60+ min) | 69 | $13,698 | $199 |
| Short return visit (20+ min) | 101 | $11,608 | $76 |
| Removal of lymph nodes of both sides of pelvis and abdominal lymph node biopsy using an endoscope | 12 | $4,856 | $405 |
2020: 7 services
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 27 | $17,550 | $650 |
| Long return visit (40+ min) | 62 | $16,529 | $123 |
| New patient visit (60+ min) | 80 | $14,689 | $184 |
| Return visit (30+ min) | 71 | $12,636 | $94 |
| Short return visit (20+ min) | 132 | $12,119 | $62 |
| Removal of lymph nodes of both sides of pelvis and abdominal lymph node biopsy using an endoscope | 11 | $8,837 | $803 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $2,300 | $96 |
2019: 6 services
| Long return visit (40+ min) | 69 | $20,066 | $131 |
| New patient visit (60+ min) | 75 | $13,600 | $181 |
| Short return visit (20+ min) | 124 | $11,263 | $63 |
| Removal of lymph nodes of both sides of pelvis and abdominal lymph node biopsy using an endoscope | 16 | $10,836 | $677 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 17 | $9,724 | $572 |
| Return visit (30+ min) | 72 | $8,532 | $88 |
2018: 7 services
| Removal of lining of abdomen, uterus, ovaries, fallopian tubes, and lymph nodes of pelvis and aorta for reduction of growth | 12 | $23,088 | $1,924 |
| Long return visit (40+ min) | 64 | $20,871 | $126 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, more than 250.0 g | 19 | $17,642 | $929 |
| New patient visit (60+ min) | 87 | $15,432 | $177 |
| Return visit (30+ min) | 98 | $15,214 | $92 |
| Short return visit (20+ min) | 130 | $12,101 | $58 |
| Release of scar tissue at ureter | 16 | $11,154 | $697 |
2017: 6 services
| Long return visit (40+ min) | 52 | $15,816 | $128 |
| New patient visit (60+ min) | 90 | $15,742 | $175 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 18 | $12,935 | $719 |
| Return visit (30+ min) | 87 | $12,494 | $92 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, more than 250.0 g | 12 | $11,927 | $994 |
| Short return visit (20+ min) | 110 | $10,754 | $58 |
2016: 7 services
| New patient visit (60+ min) | 83 | $15,321 | $185 |
| Return visit (30+ min) | 71 | $12,704 | $93 |
| Long return visit (40+ min) | 49 | $12,242 | $135 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, more than 250.0 g | 11 | $11,845 | $1,077 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 16 | $10,318 | $645 |
| Removal of lymph nodes of both sides of pelvis and abdominal lymph node biopsy using an endoscope | 14 | $8,275 | $591 |
| Short return visit (20+ min) | 84 | $7,208 | $62 |
2015: 6 services
| New patient visit (60+ min) | 99 | $18,955 | $191 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 19 | $14,204 | $748 |
| Return visit (30+ min) | 53 | $9,264 | $101 |
| Short return visit (20+ min) | 70 | $6,341 | $67 |
| Long return visit (40+ min) | 29 | $6,126 | $142 |
| Diagnostic exam of bladder and urethra using an endoscope | 12 | $778 | $60 |
2014: 5 services
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 21 | $17,470 | $832 |
| New patient visit (60+ min) | 82 | $15,330 | $187 |
| Return visit (30+ min) | 45 | $5,495 | $95 |
| Long return visit (40+ min) | 18 | $3,096 | $135 |
| Short return visit (20+ min) | 38 | $3,087 | $61 |
2013: 8 services
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 24 | $21,875 | $911 |
| Return visit (30+ min) | 59 | $7,478 | $66 |
| Short return visit (20+ min) | 65 | $5,508 | $44 |
| Short return visit (20+ min) | 41 | $4,463 | $63 |
| New patient visit (45+ min) | 17 | $2,592 | $152 |
| New patient visit (45+ min) | 18 | $1,996 | $111 |
| Long return visit (40+ min) | 15 | $1,741 | $97 |
| New patient visit (30+ min) | 17 | $1,132 | $67 |
Drugs they prescribed that Part D paid
$108,385
Pharmacies billed $108,385 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 57% of their Part D prescriptions (61 of 108) in 2024. A higher opioid share than 9 in 10 peers; the typical gynecological oncology clinician is at 13%.
98 generic and fewer than 11 brand-name prescriptions · $108,385 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Letrozole | 11 | $506 | $46 |
| Acetaminophen-Codeine | 48 | $156 | $3 |
| Hydrocodone-Acetaminophen | 12 | $31 | $3 |
Year by year
| 2024 | 108 | 79 | 57% (61) | None | $108,385 |
| 2023 | 85 | 66 | 64% (54) | None | $11,381 |
| 2022 | 91 | 68 | 59% (54) | None | $3,512 |
| 2021 | 98 | 83 | 76% (74) | None | $2,167 |
| 2020 | 137 | 103 | 64% (88) | 10% | $122,005 |
| 2019 | 157 | 98 | 45% (71) | 24% | $406,842 |
| 2018 | 211 | 101 | 46% (96) | 26% | $572,384 |
| 2017 | 204 | 105 | 43% (87) | 7% | $72,975 |
| 2016 | 160 | 100 | 66% (105) | None | $3,665 |
| 2015 | 110 | 70 | 55% (60) | None | $3,718 |
| 2014 | 89 | 58 | 51% (45) | None | $3,410 |
| 2013 | 100 | 39 | 19% (19) | 12% | $8,990 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Hydrocodone-Acetaminophen | 50 | $173 | $3 |
2022: 1 drug
| Hydrocodone-Acetaminophen | 51 | $304 | $6 |
2021: 1 drug
| Hydrocodone-Acetaminophen | 66 | $573 | $9 |
2020: 2 drugs
| Hydrocodone-Acetaminophen | 70 | $561 | $8 |
| Acetaminophen-Codeine | 14 | $186 | $13 |
2019: 2 drugs
| Lynparza | 20 | $295,165 | $14,758 |
| Hydrocodone-Acetaminophen | 68 | $834 | $12 |
2018: 4 drugs
| Lynparza | 20 | $288,621 | $14,431 |
| Zejula | 15 | $242,742 | $16,183 |
| Hydrocodone-Acetaminophen | 87 | $1,290 | $15 |
| Gabapentin | 13 | $507 | $39 |
2017: 5 drugs
| Hydrocodone-Acetaminophen | 74 | $489 | $7 |
| Dexamethasone | 16 | $108 | $7 |
| Ondansetron | 15 | $106 | $7 |
| Lorazepam | 13 | $44 | $3 |
| Prochlorperazine Maleate | 11 | $37 | $3 |
2016: 2 drugs
| Acetaminophen-Codeine | 56 | $714 | $13 |
| Hydrocodone-Acetaminophen | 43 | $601 | $14 |
2015: 1 drug
| Acetaminophen-Codeine | 57 | $624 | $11 |
2014: 1 drug
| Hydrocodone-Acetaminophen | 32 | $279 | $9 |
2013: 2 drugs
| Lorazepam | 19 | $102 | $5 |
| Hydrocodone-Acetaminophen | 11 | $92 | $8 |
Money from drug and device companies
$338,199 in 2025
| 2025 | 12 | 201 | $309,289 | $338,199 |
| 2024 | 10 | 193 | $307,622 | $339,389 |
| 2023 | 8 | 181 | $251,000 | $284,298 |
| 2022 | 7 | 194 | $248,287 | $285,918 |
| 2021 | 10 | 109 | $177,256 | $193,807 |
| 2020 | 6 | 98 | $104,273 | $113,496 |
| 2019 | 8 | 409 | $354,893 | $425,439 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| GlaxoSmithKline | Jemperli | $137,769 | 78 payments
|
| Eisai | Lenvima | $81,693 | 48 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $63,020 | 28 payments
|
| Abbvie | Elahere | $21,958 | 11 payments
|
| Genmab U.S. | Tivdak | $19,577 | 13 payments
|
| Pfizer | Tivdak | $12,139 | 11 payments
|
See all 200 published payments
| Genmab U.S. | Travel · 2025-12-30 | Tivdak | $8 |
| Corcept Therapeutics | Meals · 2025-12-13 | None | $50 |
| Corcept Therapeutics | Meals · 2025-12-13 | None | $80 |
| Corcept Therapeutics | Meals · 2025-12-12 | Korlym | $69 |
| Corcept Therapeutics | Travel · 2025-12-12 | None | $161 |
| Corcept Therapeutics | Meals · 2025-12-12 | None | $80 |
| Genmab U.S. | Paid to speak or teach · 2025-12-11 | Tivdak | $5,750 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-12-08 | Lynparza | $4,920 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-04 | Lynparza | $121 |
| GlaxoSmithKline | Meals · 2025-12-02 | Jemperli | $95 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-12-02 | Lynparza | $6,560 |
| GlaxoSmithKline | Paid to speak or teach · 2025-12-01 | Jemperli | $2,850 |
| GlaxoSmithKline | Paid to speak or teach · 2025-12-01 | Jemperli | $5,700 |
| GlaxoSmithKline | Paid to speak or teach · 2025-11-25 | Jemperli | $5,700 |
| Genmab U.S. | Paid to speak or teach · 2025-11-24 | Tivdak | $5,750 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-20 | Lynparza | $114 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-11-20 | Lynparza | $110 |
| Eisai | Travel · 2025-11-20 | Lenvima | $591 |
| Genmab U.S. | Travel · 2025-11-19 | Tivdak | $16 |
| Eisai | Travel · 2025-11-19 | Lenvima | $1,027 |
| Eisai | Paid to speak or teach · 2025-11-18 | Lenvima | $2,263 |
| Eisai | Paid to speak or teach · 2025-11-18 | Lenvima | $2,715 |
| Eisai | Meals · 2025-11-18 | Lenvima | $125 |
| Genmab U.S. | Meals · 2025-11-13 | Tivdak | $101 |
| GlaxoSmithKline | Travel · 2025-11-12 | Jemperli | $240 |
| GlaxoSmithKline | Meals · 2025-11-12 | Jemperli | $101 |
| GlaxoSmithKline | Travel · 2025-11-12 | Jemperli | $565 |
| GlaxoSmithKline | Travel · 2025-11-11 | Jemperli | $562 |
| GlaxoSmithKline | Meals · 2025-11-11 | Jemperli | $57 |
| GlaxoSmithKline | Travel · 2025-11-11 | Jemperli | $885 |
| GlaxoSmithKline | Paid to speak or teach · 2025-11-05 | Jemperli | $475 |
| Eisai | Meals · 2025-10-30 | Lenvima | $27 |
| Genmab U.S. | Travel · 2025-10-27 | Tivdak | $8 |
| Genmab U.S. | Paid to speak or teach · 2025-10-21 | Tivdak | $4,625 |
| Eisai | Meals · 2025-10-18 | Lenvima | $79 |
| Genmab U.S. | Travel · 2025-10-14 | Tivdak | $272 |
| GlaxoSmithKline | Paid to speak or teach · 2025-10-10 | Zejula | $950 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-10-08 | Lynparza | $2,460 |
| Genmab U.S. | Meals · 2025-10-04 | Tivdak | $31 |
| GlaxoSmithKline | Consulting · 2025-10-03 | Jemperli | $4,800 |
| GlaxoSmithKline | Travel · 2025-10-03 | Jemperli | $20 |
| GlaxoSmithKline | Meals · 2025-10-03 | Jemperli | $84 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-10-02 | Lynparza | $6,560 |
| GlaxoSmithKline | Paid to speak or teach · 2025-09-23 | Jemperli | $3,800 |
| Abbvie | Consulting · 2025-09-22 | Elahere | $3,488 |
| Abbvie | Consulting · 2025-09-19 | None | $3,100 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-09-19 | Lynparza | $1,640 |
| Genmab U.S. | Travel · 2025-09-18 | Tivdak | $325 |
| Genmab U.S. | Travel · 2025-09-18 | Tivdak | $166 |
| GlaxoSmithKline | Paid to speak or teach · 2025-09-08 | Jemperli | $5,700 |
| GlaxoSmithKline | Meals · 2025-09-03 | Jemperli | $122 |
| GlaxoSmithKline | Consulting · 2025-08-28 | Jemperli | $2,000 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-08-28 | Lynparza | $605 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-08-28 | Lynparza | $135 |
| Eisai | Meals · 2025-08-27 | Lenvima | $125 |
| Eisai | Paid to speak or teach · 2025-08-27 | Lenvima | $2,038 |
| Eisai | Paid to speak or teach · 2025-08-27 | Lenvima | $2,038 |
| Eisai | Paid to speak or teach · 2025-08-27 | Lenvima | $4,890 |
| Eisai | Paid to speak or teach · 2025-08-27 | Lenvima | $6,520 |
| Eisai | Travel · 2025-08-23 | Lenvima | $201 |
| Eisai | Travel · 2025-08-21 | Lenvima | $626 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-08-20 | Lynparza | $1,640 |
| Genmab U.S. | Meals · 2025-08-20 | Tivdak | $125 |
| GlaxoSmithKline | Meals · 2025-08-13 | Jemperli | $118 |
| GlaxoSmithKline | Travel · 2025-08-13 | Jemperli | $412 |
| GlaxoSmithKline | Travel · 2025-08-13 | Jemperli | $306 |
| GlaxoSmithKline | Paid to speak or teach · 2025-08-08 | Jemperli | $5,700 |
| Abbvie | Paid to speak or teach · 2025-08-07 | Elahere | $3,875 |
| Abbvie | Meals · 2025-08-07 | Elahere | $109 |
| Genmab U.S. | Consulting · 2025-07-25 | Epkinly | $2,400 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-07-24 | Lynparza | $1,640 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-07-24 | Lynparza | $1,640 |
| GlaxoSmithKline | Paid to speak or teach · 2025-07-18 | Jemperli | $4,800 |
| GlaxoSmithKline | Paid to speak or teach · 2025-07-14 | Jemperli | $2,400 |
| GlaxoSmithKline | Travel · 2025-07-08 | Jemperli | $375 |
| GlaxoSmithKline | Meals · 2025-07-08 | Jemperli | $126 |
| Abbvie | Paid to speak or teach · 2025-07-02 | Elahere | $1,550 |
| Intuitive Surgical | Meals · 2025-07-01 | Da Vinci Surgical System | $126 |
| Eisai | Consulting · 2025-06-30 | Lenvima | $408 |
| Eisai | Paid to speak or teach · 2025-06-26 | Lenvima | $6,520 |
| Eisai | Paid to speak or teach · 2025-06-26 | Lenvima | $2,038 |
| Eisai | Meals · 2025-06-26 | Lenvima | $125 |
| GlaxoSmithKline | Paid to speak or teach · 2025-06-24 | Jemperli | $4,800 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-06-20 | Lynparza | $4,920 |
| GlaxoSmithKline | Travel · 2025-06-17 | Jemperli | $240 |
| GlaxoSmithKline | Travel · 2025-06-17 | Jemperli | $227 |
| GlaxoSmithKline | Meals · 2025-06-17 | Jemperli | $98 |
| Pfizer | Consulting · 2025-06-13 | Tivdak | $720 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-12 | Lynparza | $106 |
| GlaxoSmithKline | Education · 2025-06-06 | None | $65 |
| Abbvie | Paid to speak or teach · 2025-06-03 | Elahere | $3,875 |
| Eisai | Paid to speak or teach · 2025-06-02 | Lenvima | $2,038 |
| Eisai | Paid to speak or teach · 2025-06-02 | Lenvima | $6,520 |
| Eisai | Meals · 2025-06-02 | Lenvima | $125 |
| Merck Sharp & Dohme | Meals · 2025-06-01 | Keytruda | $147 |
| Eli Lilly and | Meals · 2025-05-31 | None | $57 |
| Abbvie | Meals · 2025-05-30 | Elahere | $17 |
| GlaxoSmithKline | Meals · 2025-05-29 | Jemperli | $125 |
| GlaxoSmithKline | Travel · 2025-05-29 | Jemperli | $520 |
| Eisai | Travel · 2025-05-29 | Lenvima | $1,117 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-05-28 | Lynparza | $411 |
| GlaxoSmithKline | Paid to speak or teach · 2025-05-22 | Zejula | $2,400 |
| GlaxoSmithKline | Paid to speak or teach · 2025-05-22 | Zejula | $4,800 |
| GlaxoSmithKline | Paid to speak or teach · 2025-05-22 | Jemperli | $3,200 |
| Abbvie | Meals · 2025-05-21 | Elahere | $31 |
| Pfizer | Travel · 2025-05-20 | Tivdak | $274 |
| Pfizer | Travel · 2025-05-20 | Tivdak | $274 |
| Pfizer | Paid to speak or teach · 2025-05-19 | Tivdak | $4,625 |
| Pfizer | Paid to speak or teach · 2025-05-19 | Tivdak | $5,750 |
| Pfizer | Meals · 2025-05-15 | Tivdak | $125 |
| Pfizer | Meals · 2025-05-14 | Tivdak | $124 |
| GlaxoSmithKline | Paid to speak or teach · 2025-05-12 | Zejula | $4,800 |
| Eisai | Paid to speak or teach · 2025-05-09 | Lenvima | $2,038 |
| Eisai | Meals · 2025-05-09 | Lenvima | $50 |
| Eisai | Paid to speak or teach · 2025-05-09 | Lenvima | $815 |
| Eisai | Travel · 2025-05-08 | Lenvima | $157 |
| Eisai | Travel · 2025-05-08 | Lenvima | $218 |
| Eisai | Paid to speak or teach · 2025-05-08 | Lenvima | $6,520 |
| Eisai | Paid to speak or teach · 2025-05-08 | Lenvima | $2,038 |
| Eisai | Meals · 2025-05-08 | Lenvima | $125 |
| Pfizer | Travel · 2025-05-06 | Tivdak | $33 |
| Pfizer | Travel · 2025-05-06 | Tivdak | $90 |
| Pfizer | Travel · 2025-05-06 | Tivdak | $33 |
| Pfizer | Travel · 2025-05-06 | Tivdak | $90 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-05-06 | Lynparza | $4,920 |
| GlaxoSmithKline | Paid to speak or teach · 2025-05-05 | Zejula | $2,400 |
| GlaxoSmithKline | Paid to speak or teach · 2025-05-05 | Zejula | $4,800 |
| GlaxoSmithKline | Paid to speak or teach · 2025-05-05 | Jemperli | $3,200 |
| Merck Sharp & Dohme | Education · 2025-05-02 | Keytruda | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-01 | Lynparza | $121 |
| Eisai | Travel · 2025-04-30 | Lenvima | $291 |
| GlaxoSmithKline | Paid to speak or teach · 2025-04-29 | Zejula | $3,200 |
| GlaxoSmithKline | Paid to speak or teach · 2025-04-29 | Jemperli | $4,800 |
| Eisai | Travel · 2025-04-28 | Lenvima | $630 |
| GlaxoSmithKline | Meals · 2025-04-23 | Zejula | $125 |
| GlaxoSmithKline | Travel · 2025-04-22 | Zejula | $367 |
| GlaxoSmithKline | Travel · 2025-04-22 | Zejula | $293 |
| GlaxoSmithKline | Meals · 2025-04-22 | Zejula | $82 |
| GlaxoSmithKline | Meals · 2025-04-16 | Zejula | $119 |
| GlaxoSmithKline | Travel · 2025-04-16 | Zejula | $203 |
| GlaxoSmithKline | Meals · 2025-04-14 | Zejula | $120 |
| GlaxoSmithKline | Travel · 2025-04-14 | Zejula | $247 |
| GlaxoSmithKline | Paid to speak or teach · 2025-04-09 | Zejula | $4,800 |
| GlaxoSmithKline | Travel · 2025-04-07 | Zejula | $522 |
| GlaxoSmithKline | Travel · 2025-04-07 | Jemperli | $1,985 |
| GlaxoSmithKline | Meals · 2025-04-07 | Zejula | $111 |
| GlaxoSmithKline | Meals · 2025-04-04 | Jemperli | $26 |
| GlaxoSmithKline | Travel · 2025-04-03 | Jemperli | $167 |
| GlaxoSmithKline | Meals · 2025-04-03 | Jemperli | $122 |
| GlaxoSmithKline | Travel · 2025-04-03 | Jemperli | $2,314 |
| GlaxoSmithKline | Paid to speak or teach · 2025-04-03 | Zejula | $4,800 |
| GlaxoSmithKline | Paid to speak or teach · 2025-03-25 | Zejula | $4,800 |
| GlaxoSmithKline | Meals · 2025-03-21 | Zejula | $125 |
| GlaxoSmithKline | Travel · 2025-03-21 | Zejula | $418 |
| Eisai | Meals · 2025-03-20 | Lenvima | $119 |
| Eisai | Paid to speak or teach · 2025-03-20 | Lenvima | $815 |
| Eisai | Paid to speak or teach · 2025-03-20 | Lenvima | $2,038 |
| Myriad Genetic Laboratories | Meals · 2025-03-19 | Precisetumor | $23 |
| Eisai | Paid to speak or teach · 2025-03-14 | Lenvima | $2,038 |
| Eisai | Paid to speak or teach · 2025-03-14 | Lenvima | $6,520 |
| Eisai | Meals · 2025-03-14 | Lenvima | $124 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-03-11 | Lynparza | $6,560 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-03-11 | Lynparza | $3,280 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-03-11 | Lynparza | $2,460 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-10 | Lynparza | $115 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-06 | Lynparza | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-06 | Lynparza | $118 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-03-06 | Lynparza | $262 |
| Eisai | Travel · 2025-03-05 | Lenvima | $577 |
| GlaxoSmithKline | Travel · 2025-03-04 | Zejula | $383 |
| GlaxoSmithKline | Paid to speak or teach · 2025-03-04 | Jemperli | $4,800 |
| GlaxoSmithKline | Meals · 2025-03-04 | Zejula | $120 |
| GlaxoSmithKline | Travel · 2025-03-04 | Zejula | $105 |
| Abbvie | Paid to speak or teach · 2025-02-27 | Elahere | $2,175 |
| Eisai | Consulting · 2025-02-26 | Lenvima | $2,445 |
| GlaxoSmithKline | Meals · 2025-02-25 | Zejula | $125 |
| GlaxoSmithKline | Paid to speak or teach · 2025-02-25 | Jemperli | $2,400 |
| GlaxoSmithKline | Travel · 2025-02-25 | Zejula | $203 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-24 | Lynparza | $102 |
| Abbvie | Paid to speak or teach · 2025-02-21 | Elahere | $3,625 |
| Abbvie | Meals · 2025-01-30 | Elahere | $113 |
| Eisai | Travel · 2025-01-30 | Lenvima | $441 |
| Eisai | Travel · 2025-01-30 | Lenvima | $1,259 |
| Eisai | Paid to speak or teach · 2025-01-29 | Lenvima | $2,038 |
| Eisai | Paid to speak or teach · 2025-01-29 | Lenvima | $2,038 |
| Eisai | Paid to speak or teach · 2025-01-29 | Lenvima | $2,445 |
| Eisai | Paid to speak or teach · 2025-01-29 | Lenvima | $2,445 |
| Eisai | Meals · 2025-01-29 | Lenvima | $98 |
| Eisai Co. | Consulting · 2025-01-24 | Lenvima | $1,226 |
| Eisai | Consulting · 2025-01-24 | Lenvima | $1,223 |
| GlaxoSmithKline | Paid to speak or teach · 2025-01-23 | Zejula | $4,350 |
| GlaxoSmithKline | Paid to speak or teach · 2025-01-23 | Zejula | $4,350 |
| GlaxoSmithKline | Paid to speak or teach · 2025-01-23 | Zejula | $4,350 |
| GlaxoSmithKline | Paid to speak or teach · 2025-01-23 | Zejula | $4,350 |
| GlaxoSmithKline | Travel · 2025-01-21 | Jemperli | $1,086 |
| GlaxoSmithKline | Travel · 2025-01-21 | Jemperli | $327 |
| GlaxoSmithKline | Meals · 2025-01-21 | Jemperli | $96 |
| GlaxoSmithKline | Paid to speak or teach · 2025-01-16 | Jemperli | $363 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-01-07 | Lynparza | $6,560 |
| AstraZeneca Pharmaceuticals LP | Paid to speak or teach · 2025-01-07 | Lynparza | $4,920 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $339,389
| GlaxoSmithKline | Jemperli | $93,341 | 59 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $89,333 | 46 payments
|
| Abbvie | Elahere | $51,885 | 29 payments
|
| Eisai | Lenvima | $44,835 | 26 payments
|
| Pfizer | Tivdak | $34,614 | 17 payments
|
| Genmab U.S. | Tivdak | $23,070 | 7 payments
|
| Medical Device Business Services | None | $1,266 | 2 payments
|
| Myriad Genetic Laboratories | Mychoice Cdx | $907 | 4 payments
|
| Karyopharm Therapeutics | Xpovio | $103 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $36 | 2 payments
|
2023: $284,298
| GlaxoSmithKline | Jemperli | $104,978 | 63 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $80,118 | 43 payments
|
| Eisai | Lenvima | $47,625 | 32 payments
|
| Seagen | Tivdak | $20,168 | 11 payments
|
| ImmunoGen | Elahere | $18,425 | 14 payments
|
| Genmab U.S. | Tivdak | $12,459 | 7 payments
|
| Myriad Genetic Laboratories | Precisetumor | $356 | 8 payments
|
| Ethicon US | Harmonic | $169 | 3 payments
|
2022: $285,918
| GlaxoSmithKline | Zejula | $108,374 | 56 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $95,064 | 66 payments
|
| Seagen | Tivdak | $42,084 | 24 payments
|
| Eisai | Lenvima | $28,156 | 26 payments
|
| Genmab U.S. | Tivdak | $11,632 | 9 payments
|
| Myriad Genetic Laboratories | Mychoice Cdx | $473 | 11 payments
|
| Ethicon US | Harmonic | $134 | 2 payments
|
2021: $193,807
| AstraZeneca Pharmaceuticals LP | Lynparza | $82,235 | 44 payments
|
| GlaxoSmithKline | Zejula | $82,052 | 40 payments
|
| Seagen | None | $11,362 | 5 payments
|
| Eisai | Lenvima | $9,696 | 9 payments
|
| Myriad Genetic Laboratories | Mychoice Cdx | $4,200 | 2 payments
|
| Merck Sharp & Dohme | Gardasil 9 | $3,366 | 2 payments
|
| Medical Device Business Services | None | $650 | 2 payments
|
| Epizyme | Tazverik | $225 | 2 payments
|
| Ethicon US | Harmonic | $14 | 1 payment
|
| Clovis Oncology | Rubraca | $9 | 2 payments
|
2020: $113,496
| AstraZeneca Pharmaceuticals LP | Lynparza | $51,081 | 33 payments
|
| GlaxoSmithKline | Zejula | $26,514 | 20 payments
|
| Merck Sharp & Dohme | Keytruda | $17,070 | 20 payments
|
| Clovis Oncology | Rubraca | $14,911 | 23 payments
|
| F. Hoffmann-La Roche AG | Tecentriq | $2,310 | 1 payment
|
| Seagen | None | $1,610 | 1 payment
|
2019: $425,439
| AstraZeneca Pharmaceuticals LP | Lynparza | $144,424 | 120 payments
|
| Tesaro | Zejula | $100,994 | 120 payments
|
| Merck Sharp & Dohme | Gardasil | $73,081 | 80 payments
|
| Clovis Oncology | Rubraca | $67,778 | 60 payments
|
| Genentech USA | Avastin | $18,781 | 15 payments
|
| F. Hoffmann-La Roche AG | Tecentriq | $15,889 | 6 payments
|
| Eisai | Lenvima | $4,473 | 6 payments
|
| Medtronic Vascular | Reveal Linq | $18 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| TESARO, Inc. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Hrd-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy · 2019 | Their institution | $276,545 |
| TESARO, Inc. · A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer · 2019 | Their institution | $247,420 |
| GlaxoSmithKline, LLC. · A Phase 3 Randomized Double-Blind Trial of Maintenance With Niraparib · 2020 | Their institution | $55,367 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Phase 2, Randomized Study of Mln0128 -A Dual Torc1-2 Inhibitor-, Mln0128 - Mln1117 -A Pi3ka Inhibitor-, Weekly Paclitaxel, Or the Combination of Weekly Paclitaxel and Mln0128 in Women With Advanced, Recurrent, Or Persistent Endometrial Cancer · 2019 | Their institution | $54,378 |
| Novocure Inc. · Ef-28 Engot -Ov50/ Innovate-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (Ttfields, 200khz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer · 2022 | Their institution | $50,121 |
| AstraZeneca UK Limited · Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene Brca Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments · 2020 | Their institution | $37,008 |
| Genentech, Inc. · A Phase III Multicenter Randomized Placebo Controlled Study of Atezolizumab Versus Placebo in Com · 2019 | Their institution | $32,191 |
| Genentech, Inc. · A Phase III Multicenter Randomized Placebo Controlled Study of Atezolizumab Versus Placebo in Com · 2020 | Their institution | $31,402 |
| ABBVIE INC. · Mirvetuximab Soravtansine (Mirv) With Carboplatin in Second-Line Treatment of Folate Receptor Alpha (Fr) Expressing, Platinum-Sensitive Epithelial Ovarian Cancer · 2025 | Their institution | $31,280 |
| Novocure Inc. · Ef-28 Engot -Ov50/ Innovate-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (Ttfields, 200khz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer · 2020 | Their institution | $29,811 |
| PFIZER INC. · A Randomized Openlabel Multicenter Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab Msb0010718c in Combination With Andor Following Chemotherapy in Patients With Previously Untreated Epithelial Ovarian Cancer Javelin Ovarian 100 · 2019 | Their institution | $28,637 |
| Novocure Inc. · Ef-28 Engot -Ov50/ Innovate-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (Ttfields, 200khz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer · 2021 | Their institution | $26,925 |
| Acerta Pharma LLC · A Phase 2 Proof of Concept Study of Acp 196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer · 2019 | Their institution | $24,235 |
| GlaxoSmithKline, LLC. · A Phase 1b/2 Multicohort Umbrella Study To Evaluate the Safety and Eff · 2025 | Their institution | $24,065 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Study of Sapanisertib, Combination of Sapanisertib With Mln1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer · 2020 | Their institution | $18,641 |
| GlaxoSmithKline, LLC. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter S · 2024 | Their institution | $18,335 |
| AstraZeneca UK Limited · Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene Brca Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments · 2022 | Their institution | $17,805 |
| TESARO, Inc. · A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens · 2019 | Their institution | $16,873 |
| GlaxoSmithKline, LLC. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter S · 2025 | Their institution | $16,745 |
| PFIZER INC. · A Randomized Openlabel Multicenter Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab Msb0010718c in Combination With Andor Following Chemotherapy in Patients With Previously Untreated Epithelial Ovarian Cancer · 2021 | Their institution | $14,572 |
| GlaxoSmithKline, LLC. · A Phase 2, Open-Label, Single-Arm Study To Evaluate the Safety and Eff · 2022 | Their institution | $13,445 |
| F. Hoffmann-La Roche AG · Ph 1b Study of Cobimetinib and Parp Inhibitor With Or Without Atezolizumab in Psoc · 2019 | Their institution | $10,750 |
| PFIZER INC. · A Randomized Openlabel Multicenter Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab in Combination With Chemotherapy Followed By Maintenance Therapy of Avelumab in Combination With the Poly Adenosine Diphosphate Adpribose Polymerase Parp Inhibitor Talazoparib in Patients With Previously Untreated Advanced Ovarian Cancer Javelin Ovarian Parp100 · 2019 | Their institution | $8,000 |
| F. Hoffmann-La Roche AG · Ph 1b Study of Cobimetinib and Parp Inhibitor With Or Without Atezolizumab in Psoc · 2021 | Their institution | $5,939 |
| PFIZER INC. · A Randomized Openlabel Multicenter Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab in Combination With Chemotherapy Followed By Maintenance Therapy of Avelumab in Combination With the Poly Adenosine Diphosphate Adpribose Polymerase Parp Inhibitor Talazoparib in Patients With Previously Untreated Advanced Ovarian Cancer Javelin Ovarian Parp100 · 2020 | Their institution | $5,660 |
| F. Hoffmann-La Roche AG · Ph 1b Study of Cobimetinib and Parp Inhibitor With Or Without Atezolizumab in Psoc · 2020 | Their institution | $5,000 |
| AstraZeneca UK Limited · Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene Brca Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments · 2021 | Their institution | $4,190 |
| Genentech, Inc. · A Phase III Multicenter Randomized Placebo Controlled Study of Atezolizumab Versus Placebo in Com · 2021 | Their institution | $4,056 |
| Genentech, Inc. · Gdc0032 Ph I II Solid Tumors and Breast Cancer · 2019 | Their institution | $3,835 |
| GlaxoSmithKline, LLC. · A Phase 1b/2 Multicohort Umbrella Study To Evaluate the Safety and Eff · 2022 | Their institution | $3,500 |
| PFIZER INC. · A Randomized Openlabel Multicenter Phase 3 Study To Evaluate the Efficacy and Safety of Avelumab Msb0010718c in Combination With Andor Following Chemotherapy in Patients With Previously Untreated Epithelial Ovarian Cancer Javelin Ovarian 100 · 2020 | Their institution | $3,202 |
| Roche Products Limited · Ph 1b Study of Cobimetinib and Parp Inhibitor With Or Without Atezolizumab in Psoc · 2019 | Their institution | $2,813 |
| GlaxoSmithKline, LLC. · A Phase 1b/2 Multicohort Umbrella Study To Evaluate the Safety and Eff · 2023 | Their institution | $2,180 |
| Novocure Inc. · Ef-28 Engot -Ov50/ Innovate-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (Ttfields, 200khz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer · 2023 | Their institution | $1,628 |
| Novocure Inc. · Ef-28 Engot -Ov50/ Innovate-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (Ttfields, 200khz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer · 2024 | Their institution | $814 |
| AstraZeneca Pharmaceuticals LP · This Is A Non Randomized Open Label Study To Assess Olaparib Tablets As A Treatment for Subjects With Different Homologous Recombination Deficiency Hrd Tumor Status and With Platinum Sensitive Relapsed High Grade Ovarian Cancer Subjects Should Have Received at Least 2 Prior Lines of Platinum Based Chemotherapy · 2020 | Their institution | $500 |
| F. Hoffmann-La Roche AG · Ph 1b Study of Cobimetinib and Parp Inhibitor With Or Without Atezolizumab in Psoc · 2023 | Their institution | $500 |
| Merck Sharp & Dohme Corporation · A Phase 2 Proof-of-Concept Study of Acp-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer · 2021 | Their institution | $115 |
Professional record
- NPI
- 1962596551
- Licence
- CA A61661California A61661: Current · expires 2029-02-28
- Trained
- University of California, Geffen School of Medicine, 1995 · 31 years ago
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207VX0201X (207VX0201X); Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2006-10-03
- NPI last updated
- 2020-05-28
- NPI record certified
- 2020-05-28
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 751 S Bascom Ave, San Jose, CA, 95128